Search results for "rabin"

showing 10 items of 184 documents

Active Site Mapping of Xylan-Deconstructing Enzymes with Arabinoxylan Oligosaccharides Produced by Automated Glycan Assembly

2017

Xylan-degrading enzymes are crucial for the deconstruction of hemicellulosic biomass, making the hydrolysis products available for various industrial applications such as the production of biofuel. To determine the substrate specificities of these enzymes, we prepared a collection of complex xylan oligosaccharides by automated glycan assembly. Seven differentially protected building blocks provided the basis for the modular assembly of 2-substituted, 3-substituted, and 2-/3-substituted arabino- and glucuronoxylan oligosaccharides. Elongation of the xylan backbone relied on iterative additions of C4-fluorenylmethoxylcarbonyl (Fmoc) protected xylose building blocks to a linker-functionalized …

GlycanGlycoside HydrolasesStereochemistryOligosaccharidesSOLID-PHASE SYNTHESISXylose010402 general chemistryARABINOXYLANPLANT CELL WALL01 natural sciencesCatalysisSubstrate Specificity//purl.org/becyt/ford/1 [https]chemistry.chemical_compoundHydrolysisCellvibrioGlucuronoxylanCatalytic DomainArabinoxylan//purl.org/becyt/ford/1.4 [https]Organic chemistryBacteroidesGlycoside hydrolaseSolid-Phase Synthesis Techniqueschemistry.chemical_classificationbiology010405 organic chemistryHydrolysisCARBOHYDRATESOtras Ciencias QuímicasOrganic ChemistryCiencias QuímicasActive siteGeneral ChemistryXylan0104 chemical sciencescarbohydrates (lipids)Xylosidaseschemistrybiology.proteinXylansENZYMESCIENCIAS NATURALES Y EXACTAS
researchProduct

Gmina wyznaniowa żydowska w Lututowie w okresie międzywojennym

2020

Społeczność żydowska w okresie międzywojennym w powiecie wieluńskim zajmowała ważne miejsce w społeczeństwie. W odróżnieniu od innych jego części, w Lututowie przeważali wyznawcy judaizmu. Celem podjętych badań jest ukazanie specyfiki działalności gminy wyznaniowej żydowskiej w Lututowie w okresie II Rzeczypospolitej. Bazę źródłową stanowią archiwalia, znajdujące się w Archiwum Państwowym w Łodzi – oddziale w Sieradzu, zebrane przez Starostwo Powiatowe Wieluńskie w omawianym okresie. Zastosowano metody: analizy źródeł archiwalnych, syntezy, demograficzną, geograficzną i statystyczną, a następnie przedstawiono zagadnienie w układzie problemowym. Badania źródłowe umożliwiły przedstawienie skł…

II RzeczpospolitaLututówgmina wyznaniowa żydowskarabinŻydzi
researchProduct

Profesors Viktors Ivbulis: biobibliogrāfiskais rādītājs

1993

Saturs: Priekšvārds. Profesors Viktors Ivbulis. / LZA akadēmiķis Jānis Kalniņš / Profesora V. Ivbuļa publicētie darbi. (1966. - 1992.) Profesora V. Ivbuļa atdzejotie un tulkotie darbi. Profesora V. Ivbuļa sastādītie un rediģētie darbi. Raksti par profesoru V. Ivbuli. Profesora V. Ivbuļa darbu alfabētiskais rādītājs. Personu alfabētiskais rādītājs.

Indijas civilizācija - bibliogrāfiskais rādītājsFiloloģijas zinātņu profesori Latvijas UnivesitātēProfessors of the Latvian University:HUMANITIES and RELIGION::Aesthetic subjects::Literature [Research Subject Categories]Indiešu literatūras vēsture - bibliogrāfiskais rādītājsLiteratūrzinātne - bibliogrāfiskais rādītājsBiobibliogrāfiskie rādītājiHistory of the University of LatviaBengāļu literatūras vēsture - bibliogrāfiskais rādītājsTagores Rabindranata daiļrade - bibliogrāfiskais rādītājsLatvijas Universitātes vēstureLatvijas Universitātes profesoriBengāļu literatūras kritika - bibliogrāfiskais rādītājsP. Stučkas Latvijas Valsts universitātes profesori
researchProduct

A novel galactose- and arabinose-specific lectin from the sponge Pellina semitubulosa: isolation, characterization and immunobiological properties.

1992

A new lectin from the sponge Pellina semitubulosa is derived which was extracted and purified to homogeneity. The purified lectin is probably a hexamer of polypeptide chains (each M(r) 34,000) which are covalently linked via disulfide linkages; the isoelectric point is 6.1. The lectin displays the following specificities: D-galactose (50% inhibition of hemagglutination at 0.2 mM) = L-arabinose (0.2 mM) greater than D-fucose (1.5 mM) greater than D-glucose (3.0 mM). It precipitates human erythrocytes (A1, A2, A1B, B, and O) with a titer between 2(8) and 2(11) and erythrocytes from sheep and rabbits with a titer between 2(5) and 2(10). The Pellina lectin displays a strong mitogenic effect on …

Interleukin 2HemagglutinationChemical PhenomenaLymphocyte ActivationBiochemistrySubstrate Specificitychemistry.chemical_compoundLectinsmedicineAnimalsLymphocytesAmino AcidsbiologyChemistry PhysicalMacrophagesInterleukinLectinGalactoseGeneral MedicineHemagglutination TestsMolecular biologyArabinosePoriferaTiterIsoelectric pointchemistryBiochemistryConcanavalin AGalactosebiology.proteinInterleukin-2medicine.drugInterleukin-1Biochimie
researchProduct

L-Arabinose adsorption on a Ru cluster

2011

L-Arabinose ruthenium DFT
researchProduct

L-arabinose adsorption on hydrogenated and hydrated ruthenium catalyst

2012

L-arabinose ruthenium catalysis
researchProduct

Phenolic-glycolipid-1 and lipoarabinomannan preferentially modulate TCR- and CD28-triggered proximal biochemical events, leading to T-cell unresponsi…

2012

Abstract Background Advanced stages of leprosy show T cell unresponsiveness and lipids of mycobacterial origin are speculated to modulate immune responses in these patients. Present study elucidates the role of phenolicglycolipid (PGL-1) and Mannose-capped lipoarabinomannan (Man-LAM) on TCR- and TCR/CD28- mediated signalling. Results We observed that lipid antigens significantly inhibit proximal early signalling events like Zap-70 phosphorylation and calcium mobilization. Interestingly, these antigens preferentially curtailed TCR-triggered early downstream signalling events like p38 phosphorylation whereas potentiated that of Erk1/2. Further, at later stages inhibition of NFAT binding, IL-2…

LipopolysaccharidesEndocrinology Diabetes and MetabolismT-LymphocytesClinical BiochemistryPGL-1Man-LAMGene ExpressionLymphocyte ActivationJurkat cellsJurkat CellsEndocrinologyT-cell activationIL-2 receptorPhosphorylationExtracellular Signal-Regulated MAP KinasesPromoter Regions Geneticlcsh:RC620-627Protein Kinase CImmunity CellularZAP-70 Protein-Tyrosine KinaseCD28hemic and immune systemsCell biologyMycobacterium lepraelcsh:Nutritional diseases. Deficiency diseasesmedicine.anatomical_structureHost-Pathogen InteractionsProtein BindingMAP Kinase Signaling SystemT cellReceptors Antigen T-Cellchemical and pharmacologic phenomenaBiologyImmune systemCD28 AntigensLeprosymedicineHumansSecretionCalcium SignalingCell ProliferationBiochemistry medicalAntigens BacterialLipoarabinomannanNFATC Transcription FactorsResearchBiochemistry (medical)T-cell receptorInterleukin-2 Receptor alpha SubunitMycobacteriaGene Expression RegulationAnergyImmunologyLeukocytes MononuclearInterleukin-2GlycolipidsLipids in Health and Disease
researchProduct

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

2017

Cytarabine is considered the most effective chemotherapeutic option in acute myeloid leukemia (AML). The impact of 10 polymorphisms in cytarabine metabolic pathway genes were evaluated in 225 adult de novo AML patients. Variant alleles of DCK rs2306744 and CDA rs602950 showed higher complete remission (p = .024, p = .045), with lower survival rates for variant alleles of CDA rs2072671 (p = .015, p = .045, p = .032), rs3215400 (p = .033) and wild-type genotype of rs602950 (p = .039, .014). Induction death (p = .033) and lower survival rates (p = .021, p = .047) were correlated to RRM1 rs9937 variant allele. In addition, variant alleles of CDA rs532545 and rs602950 were related to skin toxici…

Male0301 basic medicineOncologyCancer ResearchPharmacogenomic VariantsefficacyKaplan-Meier Estimatepolymorphism0302 clinical medicinePolymorphism (computer science)GenotypeRemission InductionCytarabineDCKMyeloid leukemiaHematologyMiddle AgedPrognosisLeukemia Myeloid AcuteOncology030220 oncology & carcinogenesisToxicityFemaleMetabolic Networks and Pathwaysmedicine.drugAdultAntimetabolites Antineoplasticmedicine.medical_specialtyAdolescentGenotypeacute myeloid leukemiaPolymorphism Single NucleotideYoung Adult03 medical and health sciencesInternal medicinemedicineMucositisHumansAlleleAllelesAgedRetrospective StudiesPolymorphism Geneticbusiness.industrymedicine.diseaseMinor allele frequency030104 developmental biologyCDAImmunologyCytarabinebusiness
researchProduct

Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents

2017

Purpose Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-line treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA failure in some countries, but their effect on disease progression and overall survival (OS) is unknown. Here, we analyzed outcome after ESA failure and the effect of second-line treatments. Patients and Methods We examined an international retrospective cohort of 1,698 patients with non-del(5q) lower-risk MDS treated with ESAs. Results Erythroid response to ESAs was 6…

MaleCancer Research0302 clinical medicineRecurrenceRisk Factorshemic and lymphatic diseasesHydroxyureaCumulative incidenceTreatment FailureEnzyme InhibitorsLenalidomideAged 80 and overCytarabineAnemiaMiddle AgedThalidomideMelodysplastic syndromeSurvival RateLeukemia Myeloid AcuteOncologyInternational Prognostic Scoring System030220 oncology & carcinogenesisRetreatmentAzacitidineCyclosporineDisease ProgressionChromosomes Human Pair 5FemaleChromosome DeletionErythrocyte Transfusionmedicine.drugmedicine.medical_specialtyMelodysplastic syndrome erytropoiesis stimulating agents 5q-erytropoiesis stimulating agentsDecitabineAntineoplastic AgentsTretinoinDecitabineLower risk5q-Arsenic03 medical and health sciencesInternal medicinemedicineHumansImmunologic FactorsSurvival rateAgedAntilymphocyte SerumRetrospective StudiesLenalidomidebusiness.industryValproic AcidMyelodysplastic syndromesRetrospective cohort studymedicine.diseaseMyelodysplastic SyndromesHematinicsPhysical therapybusiness030215 immunology
researchProduct

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted …

2013

Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. Patients and Methods We conducted an open-label, multicenter, randomized trial among adult patients with previously untreated stages II to IV FL to compare efficacy of eight doses of R associated with eight cycles of cyclophosphamide, vincristine, and prednisone (CVP) or six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or six cycles of fludarabine and mitoxantrone (FM). The principal end point of the study was time to treatment failure (TTF). Results There were 534 patients…

MaleCancer ResearchLymphomamedicine.medical_treatmentFollicular lymphomaCHOPGastroenterologyAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularNON-HODGKINS-LYMPHOMASAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Vincristine; Oncology; Cancer ResearchCHEMOTHERAPYMiddle AgedPrognosisChemotherapy regimenFludarabineSurvival RateOncologyVincristineFemaleFLUDARABINECLINICAL-TRIALSVidarabinemedicine.drugAdultVincristinemedicine.medical_specialtyAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; VincristineInternal medicinemedicineHumansRITUXIMABSurvival rateCyclophosphamideRESPONSE CRITERIAAgedNeoplasm StagingChemotherapyMitoxantronebusiness.industryFollicularmedicine.diseasePHASE-IIISurgery1ST-LINE TREATMENTDoxorubicinPrednisoneMitoxantroneNeoplasm GradingbusinessFollow-Up StudiesJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct